EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
18. November 2024 08:00 ET
|
EnteroBiotix
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
18. November 2024 03:00 ET
|
EnteroBiotix
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis
11. November 2024 03:00 ET
|
EnteroBiotix
EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy...
EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials
04. April 2024 03:00 ET
|
EnteroBiotix
GLASGOW, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics,...
EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)
03. April 2024 03:00 ET
|
EnteroBiotix
GLASGOW, Scotland, April 03, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today...
EnteroBiotix Strengthens its Executive Team, Appoints COO and CFO
01. Februar 2024 03:27 ET
|
EnteroBiotix
GLASGOW, Scotland, Feb. 01, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage biopharmaceutical company with the premier platform for full-spectrum microbiome therapeutics,...
EnteroBiotix appoints Elmar Schnee as Executive Chairman
17. Juli 2023 03:00 ET
|
EnteroBiotix
GLASGOW, Scotland, July 17, 2023 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, today announced the...
EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy
28. März 2023 03:00 ET
|
EnteroBiotix
GLASGOW, United Kingdom, March 28, 2023 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage biotechnology company focussed on developing best-in-class full-spectrum microbiome...